ScaleReady announces a G-Rex® Grant has been awarded to LIfT Biosciences
ScaleReady, in collaboration with Wilson Wolf Manufacturing, Bio-Techne (NASDAQ: TECH), and CellReady, has awarded a $300,000 G-Rex® Grant to LIfT BioSciences. This grant will support the clinical manufacturing of LIfT's Neutrophil only Leukocyte Infusion Therapy (N-LIfT) platform, a promising allogeneic innate cell therapy.
The N-LIfT platform produces Immunomodulatory Alpha Neutrophils (IMANs), enhanced neutrophils designed to overcome treatment resistance in solid tumors. IMANs can identify and kill solid tumors irrespective of antigen, both directly and indirectly by recruiting the patient's own cancer-killing immune cells.
LIfT will collaborate with ScaleReady to establish a fully closed and semi-automated G-Rex manufacturing process suitable for late-stage clinical trials and beyond. The G-Rex Grant Program is a $20M initiative to advance cell and gene-modified cell therapy development and manufacturing.
ScaleReady, in collaborazione con Wilson Wolf Manufacturing, Bio-Techne (NASDAQ: TECH) e CellReady, ha assegnato un G-Rex® Grant di $300.000 a LIfT BioSciences. Questo finanziamento supporterà la produzione clinica della piattaforma Neutrophil only Leukocyte Infusion Therapy (N-LIfT) di LIfT, una promettente terapia cellulare innata allogenica.
La piattaforma N-LIfT produce Neutrofili Alfa Immunomodulatori (IMANs), neutrofili potenziati progettati per superare la resistenza ai trattamenti nei tumori solidi. Gli IMANs possono identificare e uccidere i tumori solidi indipendentemente dall'antigene, sia direttamente che indirettamente reclutando le cellule immunitarie del paziente che uccidono il cancro.
LIfT collaborerà con ScaleReady per stabilire un processo di produzione G-Rex completamente chiuso e semi-automatizzato adatto per le sperimentazioni cliniche avanzate e oltre. Il Programma G-Rex Grant è un
ScaleReady, en colaboración con Wilson Wolf Manufacturing, Bio-Techne (NASDAQ: TECH) y CellReady, ha otorgado una subvención G-Rex® de $300,000 a LIfT BioSciences. Esta subvención apoyará la fabricación clínica de la plataforma Terapia de Infusión de Leucocitos Solo Neutrófilos (N-LIfT) de LIfT, una prometedora terapia celular innata alogénica.
La plataforma N-LIfT produce Neutrófilos Alfa Inmunomoduladores (IMANs), neutrófilos mejorados diseñados para superar la resistencia al tratamiento en tumores sólidos. Los IMANs pueden identificar y eliminar tumores sólidos sin importar el antígeno, tanto directamente como de forma indirecta al reclutar las propias células inmunitarias del paciente que matan el cáncer.
LIfT colaborará con ScaleReady para establecer un proceso de fabricación G-Rex completamente cerrado y semi-automatizado, adecuado para ensayos clínicos en etapas avanzadas y más allá. El Programa de Subvenciones G-Rex es una iniciativa de $20M para avanzar en el desarrollo y la fabricación de terapias celulares y terapia celular modificada genéticamente.
ScaleReady는 Wilson Wolf Manufacturing, Bio-Techne (NASDAQ: TECH) 및 CellReady와 협력하여 LIfT BioSciences에 $300,000 G-Rex® Grant를 수여했습니다. 이 보조금은 LIfT의 Neutrophil only Leukocyte Infusion Therapy (N-LIfT) 플랫폼의 임상 제조를 지원합니다. 이는 유망한 동종 내재 세포 요법입니다.
N-LIfT 플랫폼은 면역조절성 알파 중성구 (IMANs)를 생성하며, 이는 고형 종양에서 치료 저항성을 극복하도록 설계된 향상된 중성구입니다. IMANs는 항원에 상관없이 고형 종양을 식별하고 죽일 수 있으며, 환자의 암을 죽이는 면역 세포를 모집하여 직접적 및 간접적으로 작용합니다.
LIfT는 ScaleReady와 협력하여 후기 임상 시험에 적합한 완전 폐쇄형 및 반자동 G-Rex 제조 공정을 구축할 것입니다. G-Rex Grant 프로그램은 세포 및 유전자 수정 세포 요법 개발 및 제조를 촉진하기 위한 $20M 이니셔티브입니다.
ScaleReady, en collaboration avec Wilson Wolf Manufacturing, Bio-Techne (NASDAQ: TECH) et CellReady, a attribué une subvention G-Rex® de 300 000 $ à LIfT BioSciences. Cette subvention soutiendra la fabrication clinique de la plateforme Traitement par infusion de leucocytes uniquement neutrophiles (N-LIfT) de LIfT, une thérapie cellulaire innée allogénique prometteuse.
La plateforme N-LIfT produit des neutrophiles alpha immunomodulateurs (IMANs), des neutrophiles améliorés conçus pour surmonter la résistance au traitement dans les tumeurs solides. Les IMANs peuvent identifier et éliminer les tumeurs solides indépendamment des antigènes, à la fois directement et indirectement en recrutant les propres cellules immunitaires tueuses de cancer du patient.
LIfT collaborera avec ScaleReady pour établir un processus de fabrication G-Rex totalement fermé et semi-automatisé, adapté aux essais cliniques avancés et au-delà. Le programme de subventions G-Rex est une initiative de 20 millions de dollars visant à faire progresser le développement et la fabrication de thérapies cellulaires et de thérapies cellulaires modifiées par génie génétique.
ScaleReady hat in Zusammenarbeit mit Wilson Wolf Manufacturing, Bio-Techne (NASDAQ: TECH) und CellReady einen $300.000 G-Rex® Grant an LIfT BioSciences vergeben. Diese Förderung wird die klinische Herstellung der Neutrophil only Leukocyte Infusion Therapy (N-LIfT) Plattform von LIfT unterstützen, die eine vielversprechende allogene innate Zelltherapie darstellt.
Die N-LIfT Plattform produziert Immunmodulatorische Alpha-Neutrophile (IMANs), verbesserte Neutrophile, die darauf ausgelegt sind, Resistenz gegen Behandlungen bei soliden Tumoren zu überwinden. IMANs können solide Tumoren unabhängig vom Antigen identifizieren und abtöten, sowohl direkt als auch indirekt, indem sie die eigenen krebsbekämpfenden Immunzellen des Patienten rekrutieren.
LIfT wird mit ScaleReady zusammenarbeiten, um einen vollständig geschlossenen und halbautomatisierten G-Rex-Herstellungsprozess zu etablieren, der für späte klinische Studien und darüber hinaus geeignet ist. Das G-Rex Grant-Programm ist eine $20M Initiative, um die Entwicklung und Herstellung von Zell- und gentherapeutisch modifizierten Zelltherapien voranzutreiben.
- LIfT BioSciences awarded $300,000 G-Rex® Grant for clinical manufacturing
- N-LIfT platform shows promise in treating solid tumors
- Collaboration with ScaleReady to establish scalable manufacturing process
- Access to exclusive support from ScaleReady's consortium of G-Rex Grant Partners
- None.
Insights
The G-Rex® Grant awarded to LIfT Biosciences is a significant development in the field of cell therapy for cancer treatment. This
The N-LIfT platform's unique mechanism of action, producing Immunomodulatory Alpha Neutrophils (IMANs), offers potential advantages over existing therapies:
- Ability to identify and kill solid tumors regardless of antigen expression
- Direct tumor cell killing
- Recruitment of the patient's own immune cells to the tumor site
The collaboration with ScaleReady to establish a closed, semi-automated G-Rex manufacturing process is important for scaling up production for late-stage clinical trials and potential commercialization. This partnership could accelerate the timeline for bringing N-LIfT to patients.
While promising, it's important to note that the therapy is still in early stages, with clinical trials yet to begin. Investors should monitor upcoming trial results to assess the platform's efficacy and safety profile in human subjects.
From a financial perspective, this grant has several implications for Bio-Techne (NASDAQ: TECH):
- Increased revenue potential: As a collaborator in ScaleReady, Bio-Techne stands to benefit from the adoption of G-Rex technology by grant recipients like LIfT Biosciences.
- Market expansion: The grant program, totaling
$20 million , could drive wider adoption of G-Rex technology in the cell and gene therapy space, potentially expanding Bio-Techne's market share. - Long-term growth prospects: If LIfT's N-LIfT platform proves successful in clinical trials, it could lead to increased demand for Bio-Techne's manufacturing solutions.
However, the immediate financial impact on Bio-Techne is likely to be minimal, given its
The grant also highlights Bio-Techne's commitment to innovation and collaboration in the biotech sector, which could enhance its reputation and attract more partnerships in the future.
- Award will support clinical manufacturing of the Company's promising Neutrophil only Leukocyte Infusion Therapy (N-LIfT) platform
John Wilson, CEO of Wilson Wolf and co-inventor of G-Rex, said: "We're eager to use our expertise to quickly create a highly efficient and scalable G-Rex manufacturing platform that will allow LIfT Biosciences to assess the potential of N-LIfT to penetrate the solid tumor microenvironment, kill cancer cells, and simultaneously recruit the patient's endogenous immune system."
Andrew Willis, Chief Development and Regulatory Officer at LIfT Biosciences, said: "Once infused, N-LIfT produces a new type of myeloid cell called an Immunomodulatory Alpha Neutrophil (IMAN) which is an enhanced neutrophil that is designed to overcome treatment resistance in solid tumours. IMANs can identify solid tumors irrespective of antigen and kill them both directly and indirectly via recruiting the patient's own cancer killing immune cells into the tumour site. We've selected G-Rex as our clinical manufacturing platform and associated expertise that comes with it to expedite our path to patient treatment."
As part of the G-Rex Grant, LIfT will collaborate with ScaleReady to establish a fully closed and semi-automated G-Rex manufacturing process suitable for scale out to late stage clinicals and beyond.
ScaleReady's G-Rex Grant Program is a
About LIfT BioSciences
LIfT Biosciences is a
The company is preparing initiatives with a range of pharmaceutical license partners to develop a portfolio of engineered CAR IMAN cell therapies to destroy a range of solid tumours. See www.LIfTbiosciences.com
Contact: ICR Consilium
Lindsey Neville, Namrata Taak
liftbiosciences@consilium-comms.com
About ScaleReady
ScaleReady provides the field of cell and gene-modfied cell therapy (CGT) with a G-Rex centric manufacturing platform that enables the world's most practical, flexible, scalable, and affordable CGT drug product development and manufacturing.
The G-Rex manufacturing platform is currently used by a rapidly growing list of over 800 organizations and is producing drug products for approximately
CGT entities relying on the breadth and scope of ScaleReady's expertise can expect to save years of time and millions of dollars on the path to CGT commercialization.
For more information about the ScaleReady G-Rex® Grant Program, please contact info@scaleready.com.
About Wilson Wolf Manufacturing
Wilson Wolf (www.wilsonwolf.com) is dedicated to simplifying cell and gene-modified cell (CGT) therapy research, process development, and manufacturing. This is being accomplished through its scalable G-Rex technology, which is used throughout the world in CGT applications ranging from basic research to commercial drug production.
Wilson Wolf's mission is to create hope for cancer patients, one G-Rex® device at a time.
About Bio-Techne Corporation
Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne, in partnership with Wilson Wolf, is creating products such as media and cytokines that are specifically tailored to G-Rex® Bioreactors, including right-sized reagent quantities in containers that are tailored to high throughput closed-system manufacturing. For more information on Bio-Techne and its brands, please visit https://www.bio-techne.com or follow the Company on social media at: Facebook, LinkedIn, Twitter or YouTube.
Contact: David Clair, Vice President, Investor Relations & Corporate Development
david.clair@bio-techne.com
612-656-4416
About CellReady LLC
CellReady is the world's first and only G-Rex centric contract development and manufacturing organization (CDMO) specializing in G-Rex based cell and gene-modified cell therapy development and manufacturing. The company offers a wide range of services to support the development and commercialization of these therapies.
CellReady's mission is to create hope for cancer patients, one G-Rex® process at a time.
View original content to download multimedia:https://www.prnewswire.com/news-releases/scaleready-announces-a-g-rex-grant-has-been-awarded-to-lift-biosciences-302271064.html
SOURCE Bio-Techne Corporation
FAQ
What is the value of the G-Rex Grant awarded to LIfT BioSciences?
What is the N-LIfT platform developed by LIfT BioSciences?
How does the N-LIfT platform work against solid tumors?
What is the total value of ScaleReady's G-Rex Grant Program?
